Skip to content

#inactivated

2 public questions tagged with this topic.

Inactivated vaccines usually require:

Inactivated vaccines usually require multiple doses and periodic boosters to achieve and sustain protective immunity because non replicating antigen provides transient immune stimulation. Initial dose primes naive B cells in draining lymph nodes producing low affinity IgM and modest IgG, small memory pool, titer often below correlate of protection threshold. Second dose administered 4-8 weeks later triggers anamnestic response with larger germinal center reaction, extensive somatic hypermutation in dark zone mediated by activation induced cytidine deaminase, affinity maturation, isotype class switching to IgG1 and IgG3 high neutralizing activity, expansion of long lived plasma cells homing bone marrow. Third dose further raises affinity. However antibody wanes over months to years because antigen depot cleared quickly unlike replicating live vaccine persisting weeks. Therefore boosters at 12-18 months and school entry maintain immunity. Examples hepatitis B series three doses at 0,1,6 months achieving seroprotection 95 percent, IPV three doses plus booster, DTP five doses. Reliance on multiple doses impacts compliance, coverage, programmatic cost, requiring tracking immunization records, reminder systems. Adjuvants reduce number but still need repeat exposures; oral live vaccines require single dose.

Ref: Plotkin Why inactivated needs multiple doses; WHO Immunization schedule; Amanna Duration.

Inactivated vaccines differ from live vaccines because they:

Inactivated vaccines fundamentally differ from live attenuated vaccines because they cannot replicate within host tissues. Inactivation achieved by chemical agents formaldehyde crosslinking proteins, beta-propiolactone alkylating nucleic acids, heat denaturation destroying polymerase enzymes, while preserving epitopes for antibody recognition. Because genome destroyed, no progeny virions produced, infection cycle aborted, inability to cause disease even if host immunocompromised. Immunologically absence of cytosolic replication reduces engagement of RIG-I, MDA5 cytosolic sensors sensing replicating RNA, resulting in weaker type I interferon and CD8 T cell response primarily relying on exogenous antigen uptake presented via MHC II to CD4 helpers producing mainly humoral immunity. Duration shorter necessitating adjuvants like aluminum hydroxide forming depot, enhancing uptake by dendritic cells, activating NLRP3 inflammasome IL-1 beta release. Inactivated vaccines include IPV, HAV, influenza split, rabies. They exhibit increased safety, no shedding, no reversion, but require higher doses often multiple injections to achieve protective titers. Distinction impacts storage, contraindications and schedule design with more boosters required to maintain herd immunity threshold.

Ref: Baxter J Clin Virol 2007 Inactivated cannot replicate; Plotkin Inactivated vs Live difference; CDC.